NASDAQ:VRTXVertex Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $238.31 -3.85 (-1.59 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$234.35Now: $238.31▼$247.4550-Day Range$199.77MA: $227.99▼$247.7852-Week Range$163.68Now: $238.31▼$249.85Volume1.97 million shsAverage Volume2.60 million shsMarket Capitalization$61.79 billionP/E Ratio52.84Dividend YieldN/ABeta1.01 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingVertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 22 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $260.15, Vertex Pharmaceuticals has a potential upside of 9.2% from its current price of $238.31.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.2 Community Rank Outperform VotesVertex Pharmaceuticals has received 1,400 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVertex Pharmaceuticals has received 780 “underperform” votes. (Add your “underperform” vote.)Community SentimentVertex Pharmaceuticals has received 64.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote “Outperform” if you believe VRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,786,640.00 in company stock.Percentage Held by InsidersOnly 0.70% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions94.00% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 29.39% in the coming year, from $6.26 to $8.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 52.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 9.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 52.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 12.85.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 1.36. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 10.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VRTX Previous Symbol CUSIP92532F10 CIK875320 Webhttp://www.vrtx.com/ Phone617-341-6100Debt Debt-to-Equity Ratio0.09 Current Ratio3.61 Quick Ratio3.49Price-To-Earnings Trailing P/E Ratio52.84 Forward P/E Ratio38.07 P/E Growth1.36 Sales & Book Value Annual Sales$4.16 billion Price / Sales14.84 Cash Flow$4.69 per share Price / Cash Flow50.81 Book Value$23.66 per share Price / Book10.07Profitability EPS (Most Recent Fiscal Year)$4.29 Net Income$1.18 billion Net Margins28.27% Return on Equity20.97% Return on Assets15.07%Miscellaneous Employees3,000 Outstanding Shares259,270,000Market Cap$61.79 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive VRTX News and Ratings via Email Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VRTX Rates by TradingView Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions How has Vertex Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRTX shares have increased by 8.2% and is now trading at $238.31. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vertex Pharmaceuticals? 28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 22 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vertex Pharmaceuticals. When is Vertex Pharmaceuticals' next earnings date? Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Vertex Pharmaceuticals. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its quarterly earnings results on Thursday, January, 30th. The pharmaceutical company reported $1.70 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.21 by $0.49. The pharmaceutical company had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.01 billion. Vertex Pharmaceuticals had a return on equity of 20.97% and a net margin of 28.27%. The company's quarterly revenue was up 62.4% compared to the same quarter last year. During the same period last year, the business earned $1.30 EPS. View Vertex Pharmaceuticals' earnings history. How will Vertex Pharmaceuticals' stock buyback program work? Vertex Pharmaceuticals announced that its board has initiated a share buyback plan on Wednesday, July 31st 2019, which allows the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's leadership believes its stock is undervalued. What guidance has Vertex Pharmaceuticals issued on next quarter's earnings? Vertex Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5.1-5.3 billion, compared to the consensus revenue estimate of $4.87 billion. What price target have analysts set for VRTX? 28 analysts have issued 1 year price objectives for Vertex Pharmaceuticals' shares. Their forecasts range from $195.00 to $300.00. On average, they expect Vertex Pharmaceuticals' stock price to reach $260.15 in the next year. This suggests a possible upside of 9.2% from the stock's current price. View analysts' price targets for Vertex Pharmaceuticals. What are Wall Street analysts saying about Vertex Pharmaceuticals stock? Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock: 1. Maxim Group analysts commented, "Vertex reported 2Q19 with cystic fibrosis (CF) revenue of $940M, beating consensus of $886.2M, up 25% y/y and 10% sequentially. All three approved CF drugs beat consensus; Kalydeco $262M vs. $254.5M, Orkambi $316M vs. $284.2M, and Symdeko $362M vs. $340.8M. Topline flowed through to the bottom line with $1.26 beating consensus of $1.07. Vertex ended the period with $4B in cash." (8/2/2019) 2. HC Wainwright analysts commented, "Our price target of $220/share, is based on an equally weighted composite of: (a) $216/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.94 discounted back to and (b) an NPV of $224/share (discount rate 11.0%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) the failure of in further combination clinical studies; (2) the failure of to achieve our peak sales revenue; and (3) product competition." (8/1/2019) 3. Needham & Company LLC analysts commented, "Vertex reported $857M in 1Q19 WW Cystic Fibrosis sales, above our $842M and consensus $849M ests. Symdeko/ Symkevi is primary growth driver, as expected. Sales and OpEx guidance are unch. Non-GAAP EPS was $1.14, above our $1.04 and consensus $1.01 ests. Full data set from both triple drug CF Phase 3 programs expected in 2Q19 and mgmt reiterated plans to select best regimen for NDA and MAA submissions in 3Q19 and 4Q19, respectively. Vertex moving a new once- daily corrector (VX-121) into triple drug Phase 2 trial w/ VX-561/TEZ in hopes of even greater efficacy. VX-814 announced as first candidate for AAT . A Phase 1 trial is underway w/ more backup cmpds to move into clinic in 2019. NaV1.8 pain strategy update likely in 2H19. BUY. Vertex likely to hold strong competitive position in CF for several yrs." (5/1/2019) Has Vertex Pharmaceuticals been receiving favorable news coverage? Press coverage about VRTX stock has trended very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vertex Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutVertex Pharmaceuticals. Who are some of Vertex Pharmaceuticals' key competitors? Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include Companhia de Saneamento Bsc DEDSP (SBS), NVIDIA (NVDA), Alibaba Group (BABA), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alphabet (GOOG), Micron Technology (MU), Gilead Sciences (GILD), Netflix (NFLX) and salesforce.com (CRM). Who are Vertex Pharmaceuticals' key executives? Vertex Pharmaceuticals' management team includes the following people: Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 53)Dr. Jeffrey A. Chodakewitz, Sr. Advisor (Age 63) What is Vertex Pharmaceuticals' stock symbol? Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX." Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cullinan Associates Inc. (0.04%), McGuire Investment Group LLC (0.00%) and Woodstock Corp (0.00%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, Thomas Graney, William D Young and Yuchun Lee. View institutional ownership trends for Vertex Pharmaceuticals. Which major investors are selling Vertex Pharmaceuticals stock? VRTX stock was sold by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young, and Yuchun Lee. View insider buying and selling activity for Vertex Pharmaceuticals. Which major investors are buying Vertex Pharmaceuticals stock? VRTX stock was bought by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., and Woodstock Corp. View insider buying and selling activity for Vertex Pharmaceuticals. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vertex Pharmaceuticals' stock price today? One share of VRTX stock can currently be purchased for approximately $238.31. How big of a company is Vertex Pharmaceuticals? Vertex Pharmaceuticals has a market capitalization of $61.79 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe. View additional information about Vertex Pharmaceuticals. What is Vertex Pharmaceuticals' official website? The official website for Vertex Pharmaceuticals is http://www.vrtx.com/. How can I contact Vertex Pharmaceuticals? Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Why does the United States have a lingering trade deficit?
